Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cel ...